natgillin/translations-raw huggingface dataset:
the subject taking an effective amount of a first colon cleansing solution; and then 
- primjena na subjektu djelotvorne količine prve otopine za čišćenje debelog crijeva;
An anti-IL-1B antibody or IL-1B-binding fragment thereof for use of claims 1-9, wherein the dose of the antibody or fragment is sufficient to achieve at least a 20% decrease in CRP levels. 
Anti-IL-1B protutijelo ili njegov IL-1B-vezujući fragment za uporabu prema zahtjevima 1-9, gdje je doza protutijela ili fragmenta dovoljna za postizanje barem 20% smanjenja razine C-reaktivnog proteina (CRP).
The antisense oligonucleotide of claim 1 or 2, wherein the oligonucleotide is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide. 
Antisens oligonukleotid u skladu sa zahtjevom 15, naznačen time što navedeni antisens oligonukleotid je kemijski vezan na jedan ili više ostataka ili konjugata koji poboljšavaju aktivnost, raspodjela po stanici, ili unos u stanicu antisens oligonukleotida.
Fibrids comprising poly alpha-1,3-glucan. 
Fibridi koji sadrže poli alfa-1,3-glukan.
The liquid composition of claim 9, wherein said sugar is sucrose or dextrose. 
Tekući pripravak of patentni zahtjev 11, naznačen time što je navedeni šećer saharoza ili dekstroza.
said cells express one or more additional markers selected in the group comprising alkaline phosphatase, SSEA-1, EMA-1, ENS-1,and wherein said cells do not produce replication-competent endogenous retrovirus particles. 
- < te stanice eksprimiraju jedan ili više dodatnih markera izabranih iz grupe koja obuhvaća alkalnu fosfatazu, SSEA-1, EMA-1, ENS-1,i gdje te stanice ne proizvode za replikaciju kompetentne endogene čestice retrovirusa.
The pharmaceutical composition of Claim 6, wherein the steroidal anti-inflammatory agent is 6a,9a-difluoro-17a-[(2-furanylcarbonyl)oxy]-11B-hydroxy-16a-methyl-3-oxoandrosta-1,4-diene-17B-carbothioic acid S-fluoromethyl ester or a solvate thereof. 
Farmaceutski pripravak u skladu sa zahtjevom 5, naznačen time, da je steroidno protuupalno sredstvo S-fluorometil ester 6a,9a-difluoro-17a-[(2-fu ranilkarbonil)oksi]-11B-hidroksi-16a-metil-3-oksoandrosta-1,4-dien-17B-karbotio kiseline ili njegov solvat.
As the percentage of animals protected with the combination of the two drugs (acetyl salicylic acid+compound 12) is higher than 75% (it is 100%) there is a synergism between the two products. 
Kako je postotak životinja zaštićenih s kombinacijom dvaju lijekova (acetil salicilna kiselina + spoj 12) veća od 75% (to jest 100%) ovdje postoji sinergizam između dva proizvoda. HR P20090152 T3
As mentioned above, the particles of the population of the first aspect of the invention are present in a metastable first phase and being able to undergo a martensitic transformation to a stable second phase, said transformation being effected to an extent of at least 80% within 300 sec when tested in the “Zirconia Particle Transformation Test” defined herein. 
Kao što je gore spomenuto, populacija čestica prvog aspekta iz izuma prisutnih u prvoj metastabilnoj fazi koje mogu proći kroz martenzitsku transformaciju u stabilnu drugu fazu, a rečena transformacija može biti do najmanje 80% unutar 300 sekundi kada je testirana u ovdje definiranom "Zirkonia Particle Transformation Test".
a second active selected from osmotic agents, ENaC blockers, anti-inflammatory agents, bronchodilatory agents, antihistamine agents, anti-tussive agents, antibiotic agents and DNase drug substances, wherein the first and second actives may be in the same or different pharmaceutical composition. 
Farmaceutska kombinacija, naznačena time, da obuhvaća: prvi djelatni sastojak koji sadrži spoj ili njegovu farmaceutski prihvatljivu sol, prema bilo kojem od zahtjeva 1 do drugi djelatni sastojak odabran od sljedećih: osmotska sredstva, ENaC-blokatori, protuupalna sredstva, bronhodilatorna sredstva, antihistaminska sredstva, antitusivna sredstva, antibiotici i ljekovite DNase-supstance, pri čemu prvi i drugi djelatni sastojci mogu biti u istom ili u drugačijem farmaceutskom sastavu.
The scaffold of claim 2, wherein said polymer comprises a natural polymer comprising collagen, elastin, silk, hyaluronic acid, chitosan, and any combinations thereof. 
Bioskela sukladno zahtjevu 3, pri čemu navedeni polimer dolazi kao prirodni polimer s kolagenom, elastinom, svilom, hijaluronskom kiselinom, hitozanom ili bilo kojom njihovom kombinacijom.
The foregoing method preferably further comprises the step of mounting the fixedly positioned magnetic plate (2) and the additional magnet (3) on a rotatable cylinder on a printing machine. 
Postupak sukladno bilo kojem patentnom zahtjevu 13 do 15, naznačen time, da taj postupak dodatno uključuje sljedeći korak: postavljanje fiksirane magnetske ploče (2) i dodatnog magneta (3) na rotirajući valjak na tiskarskom stroju.
Additional examples of disorders that may be treated by the disclosed methods include atrophic AMD, keratoconus, Sjogren's syndrome, myopia, ocular tumors, corneal graft rejection, corneal injury, neovascular glaucoma, corneal ulceration, corneal scarring, proliferative vitreoretinopathy, retinopathy of prematurity, retinal degeneration, chronic glaucoma, retinal detachment, and sickle cell retinopathy. 
HR P20100559T1 miopija, sindrom histoplasmoze oka, rupture Bruchove membrane, makularni edem (uključujući dijabetični makularni edem), sarkoidoza, uveitis, atrofični AMD, keratokonus, Sjčgrenov sindrom, miopija, tumori oka, odbacivanje presađene rožnice, ozljeda rožnice, neovaskularni glaukom, ulceracija rožnice, ožiljavanje rožnice, proliferativna vitreoretinopatija, prematurna retinopatija, degeneracija mrežnice, kronični glaukom, odljuštenje 5
The composition of claim 18, wherein the additional active agent is an avermectin or milbemycin. 
Veterinarski ili agrikulturni sastav prema zahtjevu 25, naznačen time, da makrociklički lakton je avermektin ili milbemicin.
The method of any one of E1-E16, E29, and E30, wherein the multiple sclerosis is primary progressive multiple sclerosis. 
Postupak, uporaba, terapijsko sredstvo, ili agonist L-21 prema bilo kojem od prethodnih zahtjeva, naznačen time da multipla skleroza je primarna progresivna multipla skleroza.
A lotion formulation having the following composition by weight is prepared: polyethylene glycol 400 
Pripremljena je formulacija losiona, koja ima slijedeći sastav po težini: 1. poletilen glikol 400
In an embodiment, the nutritional composition, the object of the invention, includes starch at a concentration of less than or equal to 5% by weight based on the total weight of the composition. 
Postupak u skladu s bilo kojim od patentnih zahtjeva & do 10, naznačen time što je sadržaj suhog materijala u tekućoj bazi najmanje 35 %, težinski, na osnovi ukupne težine tekuće baze.
The composition of claim 11, wherein the CD8a hinge domain comprises the amino acid sequence of SEQ ID NO: 21. The composition of claim 1, wherein the CD3 zeta signaling domain comprises the amino acid sequence of SEQ ID NO: 24. The composition of claim 6, wherein the scFv is encoded by a nucleic acid sequence comprising SEQ ID NO: 14. 
(i) - kostimulatorno signalno područje 4-1 BB sadrži aminokiselinsku sekvencu naznačenu u SEQ ID NO: 23; (11) CAR sadrži aminokiselinsku sekvencu naznačenu u SEQ ID NO: 12; (ili) anti-CD19 scFv je kodirano sekvencom SEQ ID NO: 14;
A disposable absorbent article, comprising a permeable top sheet, an impermeable back sheet, an absorbent core placed between the top and back sheets containing absorbent material fibres and particles of superabsorbent material, external barriers cuffs, waist and leg elastic means, a fastening system and union means; characterised in that at least 50% of these items contain sustainable or biodegradable compounds. 
Upijajući proizvod za jednokratnu upotrebu, koji se sastoji od gornjeg propusnog sloja, nepropusnog donjeg sloja, upijajuće jezgre smještene između gornjeg i donjeg sloja koji sadržava vlakna od apsorbirajućeg materijala i čestice superapsorbirajuće tvari, nabranu vanjsku stijenku, elastična sredstva za struk i noge, sustav za pričvršćivanje i sredstva za spajanje; naznačen time, da barem 50 % od tih proizvoda sadržava biorazgradive spojeve, takve biorazgradive spojeve koji su načinjeni od prirodnih spojeva, tako da se nakon određenog vremena razgrađuju i pretvaraju u manje kompleksne spojeve, sve dok se ne razgrade na svoje najosnovnije komponente, i pri čemu su biorazgradivi spojevi odabrani od:
deforming the deformable member to clamp the tip section of the hair extension to the section of the person's natural hair. 
deformiranje deformabilnog člana (200) kako bi se učvrstilo dio vrha (120) nastavka za kosu (100) na odjeljak prirodne kose osobe.
The floating lake system of claim 1, wherein the floating lake is anchored to mainland to provide an entrance to the floating lake system. 
Sustav plutajućeg jezera (1) prema zahtjevu 14, naznačen time što je plutajuće jezero usidreno na kopno kako bi se osigurao ulaz u sustav plutajućeg jezera.
A filler comprising the plurality of hollow spherical glass particles of claim 1 . 
Punilo koji sadrži više šupljih sferničnih staklenih čestica sukladno patentnom zahtjevu 1 ili 5.
the CAR is encoded by the nucleic acid sequence set forth in SEQ ID NO:8. 
(v1) CAR je kodiran sekvencom nukleinske kiseline naznačenom u sekvenci SEQ ID NO:8.
For example, the body can be covered by plastic material to achieve a flat and smooth outer surface and cover the irregularities of the engraved indicia. 
Na primjer, tijelo se može prekriti plastičnim materijalom kako bi se dobila ravna i glatka vanjska površina i prekrilo nepravilnosti ugravirane oznake.
In a further aspect the present invention provides a combination (for example for the treatment of schizophrenia, cognitive disorders or pain) of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined and one or more agents selected from carbamazepine, olanzapine, quetiapine, verapamil, lamotrigine, oxcarbazepine, risperidone, aripiprazole, ziprasidone and lithium. 
Kombinacija spoja s formulom (I) ili njegove farmaceutski prihvatljive soli kako je zatraženo u bilo kojem od zahtjeva 1 do 10 i jednog ili više sredstava odabranih od karbamazepina, olanzapina, kvetiapina, verapamila, lamotrigina, okskarbazepina, risperidona, aripiprazola, ziprasidona 1 litija.
The method of paragraph 1, wherein said parent bacterial strain is selected from Escherichia, Shigella, Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Agrobacterium, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Francisella, Brucella, Campylobacter, Klebsiella, Frankia, Bartonella, Rickettsia, Shewanella, Serratia, Enterobacter, Proteus, Providencia, Brochothrix, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Lactobacillus, Pediococcus, Leuconostoc, and Oenococcus. 
Postupak prema zahtjevu 1, naznačen time da je navedeni matični bakterijski soj odabran od bakterija Escherichia, Shigella, Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, = Listeria, - Agrobacterium, = Staphylococcus, = Streptococcus, = Enterococcus, = Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Francisella, Brucella, Campylobacter, Klebsiella, Frankia, Bartonella, Ricketisia, Shewanella, Serratia, Enterobacter, Proteus, Providencia, Brochothrix, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Lactobacillus, Pediococcus, Leuconostoc, te Oenococcus.
Method for controlling, analyzing and managing phases of conservation and/or processing of food in a mobile or fixed closed space, according to claim 7 characterized in that the master unit at the end of each phase of conserving and/or processing, gets a set of values, if these values are all inside the set safety range, automatically the next phase starts, and if these values fall outside the safety range, the device before starting the next phase will communicate and store a report of the values, and wait for instructions from the user whether to continue the process of conserving and/or processing or stop it. 
Postupak kontroliranja, analiziranja i upravljanja fazama konzerviranja i/ili obrade hrane u pokretnom ili stacionarnom zatvorenom prostoru, u skladu s patentnim zahtjevom 7, naznačen time što glavna jedinica na kraju svake faze konzerviranja i/ili obrade, dobiva skup vrijednosti, ako te vrijednosti sve ulaze u siguran raspon za skup, automatski započinje sljedeća faza, a ako te vrijednosti izlaze iz sigurnog raspona, uređaj prije započinjanja sljedeće faze šalje 1 sprema izvješće o vrijednostima, te čeka na upute od korisnika da li nastaviti s postupkom konzerviranja i/ili obrade ili ga zaustaviti.
The composition or vaccine of claim 1 or 2 for use in a method for inducing a protective response in an animal against Newcastle Disease Virus (NDV), Infectious Bursal Disease Virus (i.e., IBDV or Gumboro Disease virus) and Marek's Disease Virus (MDV), said method comprising at least one administration of the composition or vaccine. 
Pripravak ili cjepivo prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen/o time, da se upotrebljava u postupku induciranja zaštitne reakcije kod životinje, protiv NDV i opcionalno, protiv jednog ili više daljnjih ptičjih patogena, pri čemu taj postupak obuhvaća najmanje jednu primjenu pripravka ili cjepiva.
Figure 1 illustrates a core 1, substantially tubular, hollow on the inside and comprising a corrugated side wall 2. 
Slika 1 ilustrira u osnovi cjevastu, iznutra šuplju jezgru 1, sa valovitom bočnom stijenkom 2.
The method according to claim 17, wherein said second biotinylated anticancer agent comprises an anticancer agent selected from the group consisting of radioisotopes, chemotherapeutic agents, toxins and anticancer cells. 
Upotreba u skladu s patentnim zahtjevom 1, naznačena time što se navedeno sredstvo protiv raka bira iz skupine koju čine radioizotopi, kemoterapijska sredstva, toksini i antitumorske stanice.
to 50 wt.%, particularly 10 to 40 wt.% and preferably 15 to 30 wt.% of said release modifying material; 
do 50 masenih %, posebno 1 do 50 masenih %, poželjno 10 do 40 masenih % i najpoželjnije 15 do 30 masenih % navedenog materijala koji modificira oslobađanje;
The dsRNA for use any one of claims 1 to 11, wherein: 
dsRNA za uporabu prema zahtjevu 12, pri čemu
Container as claimed in one of the preceding claims, characterized in that the wall section (4) can be adjoined at an edge (7) of the pre-cut part. 
Spremnik (1) prema jednom od prethodnih patentnih zahtjeva, naznačen time da dio stijenke (4) može graničiti sa rubom (7) dijela koji prethodno odrezan, pri čemu se spomenuti rub proteže u smjeru omatanja čaše (1).
The MMVF substrate preferably has an ignition loss of up to 2 wt%, such as 0.5 to 2.0 wt%, preferably 0.8 to 1.5 wt%. MMVF substrates with this ignition loss preferably have a density in the range of 60 kg/m3 to 150 kg/m3, more preferably 80 to 130 kg/m3. 
MMVEF supstrat sukladno bilo kojem od zahtjeva 16 do 18, naznačen time, da MMVF supstrat ima gubitak izgaranja do 2 tež%, kao što je 0,5 do 2,0 tež%, poželjno 0,8 do 1,5 tež% 1 pri čemu MMVEF supstrat gustoće u rasponu od 60 kg/m3 do 150 kg/m3, poželjno od 80 do 130 kg/m3.
According to a ninth aspect, the method of the eighth aspect comprises for a given nozzle group: identifying a firing status comprises identifying firing status indicating a warm only status; communicating warm data and fire data comprises communicating warm data with an active status and communicating fire data with an inactive status indicating that the firing signal communicated to that nozzle group is to be conditionally modified by blocking the firing pulse. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što, za danu skupinu mlaznica: određivanje statusa okidanja se sastoji u određivanju statusa okidanja koji ukazuje na status samo zagrijavanja; slanje podataka o grijanju i podataka o okidanju se sastoji u slanju podataka o grijanju s aktivnim statusom i slanje podataka o okidanju s neaktivnim statusom, koji ukazuju da okidni signal poslan u tu skupinu mlaznica treba uvjetno modificirati blokiranjem okidnog impulsa.
Use according to any of the preceding articles, wherein the one or more oligomers of lactic acid has the following formula I wherein n is an integer from 2 to 25 such as, e.g., from 2 to 20, from 3 to 25, from 3 to 20, from 2 to 15, from 3 to 15, from 2 to 10, from 3 to 10, from 4 to 10, or from 4 to 9. 
Jedan ili više oligomera mliječne kiseline za uporabu prema patentnom zahtjevu 1, pri čemu je n od 2 do 20, od 3 do 25, od 3 do 20, od 2 do 15, od 3 do 15, od 2 do 10, od 3 do 10, od 4 do 10, ili od 4 do 9.
The molecular size and the concentration of HA in aqueous solution have - as it is the case with the physical properties- a considerable influence on its biological effect. 
Molekularna veličina i koncentracija HA u vodenoj otopini imaju - kao što je slučaj s fizikalnim karakteristikama značajan utjecaj na njegov biološki učinak.
The composition according to claims 1 or 2, wherein said iron (III) salt is ferric pyrophosphate; said iron (III) salt is in an amount comprised from 30 to 70%, preferably from 40 to 60% by weight. 
Čvrsti pripravak namijenjen upotrebi u liječenju poremećaja ili bolesti povezanih s nedostatkom željeza, naznačen time što sadrži: sol željeza(III), koja je feri pirofosfat, u količini koja se kreće od 30 do 70 %, težinski; i
comprises a modified sugar, optionally wherein the modified sugar is a bicyclic sugar; and/or comprises a modified nucleobase, optionally wherein the modified nucleobase is a 5-methylcytosine; and/or consists of 15 to 30, 18 to 21, 20 to 30, 20 to 29, 20 to 28, 20 to 27, 20 to 26, 20 to 25, 20 to 24, 20 to 23, 20 to 22, 20 to 21 or 20 linked nucleobases. 
(ii) obuhvaća bar jednu modificiranu internukleozidnu vezu, opcionalno gdje je internukleozidna veza fosforotioatna internukleozidna veza; i/ili (iii) obuhvaća modificirani šećer, opcionalno gdje je modificirani šećer biciklični šećer; i/ili (iv) obuhvaća modificiranu nukleobazu, opcionalno gdje je modificirana nukleobaza 5-metilcitozin; i/ili (vV) se sastoji od 15 do 30, 18 do 21, 20 do 30, 20 do 29, 20 do 28, 20 do 27, 20 do 26, 20 do 25, 20 do 24, 20 do 23, 20 do 22, 20 do 21 ili 20 povezanih nukleobaza.
An oral dosage form of a pharmaceutical composition comprising: a bisphosphonate selected from risedronate, and salts, esters, hydrates, hemihydrates, polymorphs, and solvates thereof, and combinations thereof; 
Oralni oblik za doziranje farmaceutskog sastojka koji sadrži: a) bisfosfonat odabran iz rizedronata i soli, estera, hidrata, hemihidrata, polimorfa, i solvata istih, i kombinacija istih; b) od 75 mg do 250 mg dinatrijeve EDTA: i
is selected from the group consisting ofN, CH and CR2; and the subscript m is an integer of from 0 to 2. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da spoj ima formulu: [image] pri čemu je indeks p cijeli broj od 0 do 3.
wherein z is 0, 1 or 2, R20 is selected from hydrogen, methyl, hydroxy and fluorine and R1 to R5 are as defined herein, provided that when z is 0, R20 is other than hydroxy. 
(TV) gdje z je 0, 1 ili 2, R" je izabran između vodika, metila, hidroksi i fluora, uz uvjet da kada je z jednako 0, R* nije hidroksi. 31.
The use according to claim 8, wherein the δ-amino-Y-hydroxy-w-aryl-alkanoic acid amide derivative is a compound of formula (I) wherein R1 is 3-methoxypropoxy; R2 is methoxy; and R3 and R4 are isopropyl; or a pharmaceutically acceptable salt thereof. 
Uporaba u skladu sa zahtjevom 8, naznačena time, da derivat amida 8-amino-y-hidroksi-o-aril-alkanoične kiseline je spoj formule (I) gdje R, je 3-metoksipropoksi;, R2 je metoksi; te R: i Ra su izopropil; ili je njegova farmaceutski prihvatljiva sol.
The method according to claim 23, wherein the liquid formulation is delivered in an amount as to provide 1 to 2000 grams of triazole fungicide per hectare. 
Metoda u skladu sa patentnim zahtjevom 23, naznačena time da se tekuća otopina dodaje u količini 1 do 2000 grama triazolnog fungicida po hektru.
The solar cell according to claim 14, wherein the method of making the solar cell further comprises forming the second layer in the form of an SiOx layer from the front-side n-doped area in an ozone-containing atmosphere or by use of an ozone-containing liquid. 
Postupak u skladu s u najmanju ruku patentnim zahtjevom 13, naznačen time što drugi sloj (26) je načinjen u obliku sloja od SiO, od n-dopiranog područja u atmosferi koja sadrži ozon ili uz pomoć tekućine koja sadrži ozon.
The device 1 is installed on a rotary carrousel (not shown) by means of a support structure 2 . 
Uređaj 1 je instaliran na rotirajući stroj (nije prikazan) pomoću nosive konstrukcije 2.
The vaccine for the use according to claims 28 to 29, 31-34 or the use according to claim 30-34 wherein the subject is a mammal or a bird, or the subject is selected from the group consisting of a human, a domesticated poultry species, a domesticated live stock species, a cow, pig, a sheep, a horse, and an exotic zoo animal. 
Cjepivo za uporabu u skladu sa zahtjevima 28. do 29., 31. - 34. ili uporaba prema zahtjevu 30. - 34. naznačena time što a) = subjekt je sisavac ili ptica, ili b) subjekt je odabran iz skupine koja se sastoji od čovjeka, domaće vrste peradi, domaćih vrsta goveda, krave, svinje, ovce, konja 1 egzotičnih zooloških životinja.
The method of any of claim 40, wherein the fluoroquinolone and divalent or trivalent cation are combined in a single solution. 
41. Postupak iz bilo kojeg iz patentnog zahtjeva 40, pri čemu se fluorokinolon i dvovalentni ili trovalentni kation kombiniraju u samo jednom rastvoru.
According to the reported procedure (E. E. Gilbert, Synthesis 1969, 1-10, p6), glacial acetic acid (100 ml), vigorously stirred at room temperature, is treated by bubbling SO2 gas. 
Prema objavljenom postupku (E.E. Gilbert, Synthesis 1969, 1-10, str. 6), ledenu octenu kiselinu (100 ml) se snažno miješa pri sobnoj temperaturi i pomiješa s mjehurićima plina SO».
For this purpose, a mold 70 (FIG. 3 a) may be used comprising a top half-mold 70 a and a bottom half-mold 70 b, preferably made of metal (e.g. stainless steel). 
U ovu svrhu može se koristiti kalup 70 (Slika 3a) koji se sastoji od gornje polutke kalupa 70a i donje polutke kalupa 70b, prvenstveno izrađenih od metala (na pr. nehrđajućeg čelika).
culturing a recombinant host cell comprising a nucleic acid molecule encoding the amino acid backbone of the cyclic peptide of any one of claims 1 to 16 or a vector comprising said nucleic acid molecule under conditions such that the amino acid backbone of the polypeptide of any one of claims 1 to 16 is expressed, and recovering said amino acid backbone; or chemically synthesizing the amino acid backbone of the polypeptide of any one of claims 1 to 16; and 
(i) uzgoja rekombinantne stanice-domaćina koja sadrži molekulu nukleinske kiseline koja kodira aminokiselinska okosnica cikličkog peptida u skladu s bilo kojim od patentnih zahtjeva 1 do 16, ili vektor koji sadrži navedenu molekulu nukleinske kiseline, u uvjetima koji omogućuju eksprimiranje aminokiselinske okosnice polipeptida u skladu s bilo kojim od patentnih zahtjeva 1 do 16, te prikupljanje navedene aminokiselinske okosnice; ili
A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier. 
Farmaceutski sastav koji sadrži spoj formule (I) kako je definirano u zahtjevu 1 ili njegov N-oksid ili njegova farmaceutski prihvatljiva sol ili solvat, zajedno s farmaceutski prihvatljivim nosačem.
The combination of claim 5 wherein the additional therapeutic agent is a combination of interferon-a and ribavirin or a combination of peginterferon-a and ribavirin. 
Kombinacija prema patentnom zahtjevu 5 gdje je dodatno terapeutsko sredstvo kombinacija interferona-a i ribavirina ili kombinacija peginterferona-a i ribavirina.